Active ingredientOteseconazoleCat. No. P-O043-001CAS 1340593-59-0Family · Pharmaceutical analytical standards
Oteseconazole
An oral azole antifungal with a tetrazole ring that selectively inhibits the fungal enzyme CYP51, blocking ergosterol synthesis; approved in the United States in April 2022 for recurrent vulvovaginal candidiasis. This family brings together the active ingredient.
Did you know?It was the first medicine approved in the United States specifically for the recurrent form of vulvovaginal candidiasis; during development it was known by the code VT-1161.
Go to the active ingredient →Active ingredientOteseconazoleCat. No. P-O043-001CAS 1340593-59-0No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.